Alexander Zukiwski - CASI Pharmaceuticals Chief Medical Officer

CASI
 Stock
  

USD 1.82  0.12  6.19%   

  Executive
Dr. Alexander A. Zukiwski is Chief Medical Officer of the Company. Dr. Zukiwski joined the Company in April of 2017 as Chief Medical Officer. Prior to joining the Company, Dr. Zukiwski was Chief Executive Officer and Chief Medical Officer of Arno Therapeutics and was a Director of Arno Therapeutics since 2014. At Arno his responsibilities included leading the clinical development and regulatory affairs teams to support the companys pipeline. Prior to Arno in 2007, Dr. Zukiwski served as Chief Medical Officer and Executive Vice President of Clinical Research at MedImmune. Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson Johnsons medical affairs and clinical development functions at Johnson Johnson Pharmaceutical Research Development LLC Centocor RD and Ortho Biotech. Before joining JJ, he served in clinical oncology positions at pharmaceutical companies such as HoffmannLaRoche, Glaxo Wellcome and Rhone Poulenc Rorer. Dr. Zukiwski has more than 21 years of experience in global drug development and supported the clinical evaluation and registration of many successful oncology therapeutic agents, including Taxotere, Xeloda, Procrit Eprex, Velcade, Yondelis, and Doxil. He previously served as a Member of Medical Advisory Board at Gem Pharmaceuticals, LLC and served as a Director of Ambit Biosciences Corporationrationration
Age: 60  Executive Since 2017  Ph.D    
240 864 2600  https://www.casipharmaceuticals.com
Zukiwski holds a bachelor’s degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his postgraduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.

Alexander Zukiwski Latest Insider Activity

Tracking and analyzing the buying and selling activities of Alexander Zukiwski against CASI Pharmaceuticals stock is an integral part of due diligence when investing in CASI Pharmaceuticals. Alexander Zukiwski insider activity provides valuable insight into whether CASI Pharmaceuticals is net buyers or sellers over its current business cycle. Note, CASI Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell CASI Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

CASI Pharmaceuticals Management Efficiency

CASI Pharmaceuticals has return on total asset (ROA) of (0.155) % which means that it has lost $0.155 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.273) %, meaning that it created substantial loss on money invested by shareholders. CASI Pharmaceuticals management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -54.1. The current Return on Average Assets is estimated to decrease to -29.73. CASI Pharmaceuticals Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 76.33 Million. The current Goodwill and Intangible Assets is estimated to increase to about 12.5 M, while Asset Turnover is projected to decrease to 0.21.
The company currently holds 2.9 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. CASI Pharmaceuticals has a current ratio of 3.15, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist CASI Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, CASI Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CASI Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CASI Pharmaceuticals to invest in growth at high rates of return. When we think about CASI Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

EXECUTIVE Since

Joseph RomanelliMerck Company
2015
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland. Casi Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 176 people. CASI Pharmaceuticals (CASI) is traded on NASDAQ Exchange in USA and employs 176 people. CASI Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

CASI Pharmaceuticals Leadership Team

Elected by the shareholders, the CASI Pharmaceuticals' board of directors comprises two types of representatives: CASI Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CASI Pharmaceuticals. The board's role is to monitor CASI Pharmaceuticals' management team and ensure that shareholders' interests are well served. CASI Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CASI Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Wei Zhang, President of CASI China
Ken Ren, CEO
Alexander Zukiwski, Chief Medical Officer
George Chi, CFO
WeiWu He, Chairman of the Board
Quan Zhou, Independent Director
Sara Capitelli, Vice President - Finance, Principal Accounting Officer
James Huang, Independent Director
Franklin Salisbury, Independent Director
Tak Mak, Director
Alexander Wu, Independent Director
James Goldschmidt, Chief Officer
Cynthia Hu, COO, General Counsel, Secretary
Rong Chen, Chief Medical Officer
Rajesh Shrotriya, Director
Sara CPA, VP Fin
Amanda Cui, VP Controller

CASI Pharmaceuticals Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CASI Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CASI Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CASI Pharmaceuticals' short interest history, or implied volatility extrapolated from CASI Pharmaceuticals options trading.

Pair Trading with CASI Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CASI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CASI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with CASI Pharmaceuticals

+0.65CSBRChampions Oncology Earnings Call This WeekPairCorr

Moving against CASI Pharmaceuticals

-0.82LLYEli Lilly And Sell-off TrendPairCorr
-0.69CAHCardinal Health Sell-off TrendPairCorr
-0.67BMYBristol-Myers Squibb Aggressive PushPairCorr
-0.64ABBVAbbVie Inc Sell-off TrendPairCorr
The ability to find closely correlated positions to CASI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CASI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CASI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CASI Pharmaceuticals to buy it.
The correlation of CASI Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CASI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CASI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CASI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. You can also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for analysis

When running CASI Pharmaceuticals price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is CASI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
26.4 M
Quarterly Revenue Growth YOY
0.259
Return On Assets
(0.15) 
Return On Equity
(0.27) 
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine CASI Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.